Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Consult Freyr to decode global labeling systems and turn compliance into confidence
Introduction The first glucagon-like peptide-1 receptor agonist (GLP-1) for type 2 diabetes mellitus (T2DM) was approved in 2005 and for chronic weight management in 2014
In March, the company announced a strategic pivot to move away from cheaper compounded GLP-1 drugs to expand its assortment of branded drugs
Advantages of Advanced LC-MS Approaches Higher sensitivity for trace impurities Structural confirmation of complex peptide modifications Improved characterization of biosimilar GLP-1 drugs Better stability and degradation profiling These advanced technologies greatly expand the analytical capabilities available to scientists working with peptide therapeutics
US$ 21.24
US$ 20.12
US$ 27.56
US$ 26.35
US$ 29.29
US$ 22.89
US$ 22.41
